Catenacci DVT, Tang R, Oliner K, Ang A, Loberg RD, OE, Xu P, Henderson L, Ruzzo A, Graziano F. Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations. Washington D.C., Dec. 20, 2021 . MET receptor tyrosine kinase: A molecular therapeutic target of gastric adenocarcinoma. . In November that year, Catenacci a former University of Chicago associate professor and director of the gastrointestinal oncology program at the University of Chicago School of Medicine . Natalie Reizine, Everett E. Vokes, Ping Liu, Tien M. Truong, Rita Nanda, Gini F. Fleming, Daniel V.T. In addition to these areas, Dr. Schell has special interests in diagnosing and treating hormone dysfunction conditions including endometriosis, thyroid problems, polycystic ovarian . The symptoms of Parkinson's disease and essential tremors may be similar, but there are key differences, as well. Advanced Fertility Center of Chicago. Dr Daniel Catenacci - University of Chicago, Chicago, USA. AAA: triple adaptive Bayesian designs for the identification of optimal dose combinations in dualagent dose finding trials, Jiaying Lyu, Yuan Ji, Naiqing Zhao, Daniel V.T. He has a special interest in the treatment of neuroblastoma, sarcomas and solid tumors. Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study. Quantification of MET expression using Mass Spectrometry (MS): Assay Precision and Stability in FFPE Tumor Tissue. Share this article: Facebook Catenacci, Olufunmilayo I. Olopade. Case Presentation and Review of the literature.. (Plenary Session ORAL Presentation & Best Abstract Award). John D Powderly, Samuel J Klempner, Aung Naing, Johanna Bendell, Ignacio Garrido-Laguna, Daniel V T Catenacci, Matthew H Taylor, James J Lee, Fred Zheng, Feng Zhou, Xiaohua Gong, Hema Gowda, Gregory L Beatty. , Constantine A Raptis, Alan Goldstein, Travis S Henry, Kristin K Porter, Daniel Catenacci, Aine Marie Kelly, Christopher T Kuzniewski, Andrew R Lai, Elizabeth Lee, Jason M Long, Maria D Martin, Michael F Morris, Kim L Sandler, Arlene Sirajuddin, Devaki Shilpa Surasi, Graham W Wallace, Ihab R Kamel, Edwin F Donnelly. Joseph Chao, Charles S. Fuchs, Kohei Shitara, Josep Tabernero, Kei Muro, Eric Van Cutsem, Yung-Jue Bang, Ferdinando De Vita, Gregory Landers, Chia Jui Yen, Ian Chau, Anneli Elme, Jeeyun Lee, Mustafa Ozguroglu, Daniel V.T. Catenacci DVT, Xu P, Henderson L, Pijnenburg D, van den Berg A, Ruijtenbeek R. Detection of Portal Vein (PV) Circulating Tumor Cells (CTCs) in Pancreatic Cancer (PC) patients obtained by EUS guided PV Sampling. Final Analysis of a phase IB/Randomized phase II study of Gemcitabine (G) plus Placebo (P) or Vismodegib (V), a Hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago Phase II Consortium study. Arraignment in federal court in Chicago has not yet been scheduled. Dr. Catenacci is of the University of Chicago Medical Center and Biological Sciences. Dr. Yuan Ji graduated from Fudan University with a bachelor in Mathematics, University of Wisconsin - Madison . Catenacci, 45, an oncologist and director of the gastrointestinal oncology program at the University of Chicago, was a consultant for Five Prime and worked as a clinical investigator . In this article, Dr . Dan Catenacci (U Chicago) dcatenac@bsd.uchicago.edu. Sign up for our Newsletter Enter your email. KRAS gene amplification defines a distinct molecular subgroup of gastroesopahgeal adenocarcinoma that may benefit from combined anti-MEK/AKT therapy. Tumor genome analysis includes germline genome: Are we ready for surprises? Development of a quantitative Catenacci, Minori Koshiji Rosales, Hyun Cheol Chung, Harry H. Yoon, Lin Shen, Markus Moehler, Yoon-Koo Kang, Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma, Yaniv Berger, Darryl Schuitevoerder, Charles C. Vining, Lindsay Alpert, Emily Fenton, Enal Hindi, Chih-Yi Liao, Ardaman Shergill, Daniel V.T. Catenacci. and West)--Challenging Cases (Session Chair). Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. {{ physicianArray.length }} Doctors Found. E. L. Kwak, P. LoRusso, O. Hamid, F. Janku, M. Kittaneh, D Catenacci, E. Chan, T. Bekaii-Saab, B. Amore, Y. Hwang, R. Tang, G. Ngarmchamnanrith, D. Hong. Cancer surgeons, or surgical oncologists, remove tumors, while medical oncologists treat cancers with chemotherapy. (608) 265-1700. Catenacci, Howard S. Hochster, Samuel J. Klempner. The settlement is subject to court approval. Catenacci is an associate professor of medicine, according to his LinkedIn profile and biography on the University of Chicago's website. Development and Clinical Validation of a Quantitative Mass Spectrometric Assay for immunooncology targets in FFPE Samples. 5841 S Maryland Avenue, Chicago, IL 60637 map. Catenacci, Mark Kozloff, Hedy L. Kindler, Blase N. Polite, Molecular profiling of cancer--the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic, Thomas Stricker, Daniel V.T. Dr. Daniel Catenacci, MD is a Medical Oncology Specialist in Chicago, IL. Wentian Guo, Yuan Ji, Daniel V.T. New patients are welcome. Mark Applebaum. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial. Ankit Dhiman, Charles C Vining, Hunter D D Witmer, Divya Sood, Ardaman Shergill, Hedy Kindler, Kevin K Roggin, Mitchell C Posner, Osmanuddin S Ahmed, Stanley Liauw, Sean Pitroda, Chih-Yi Liao, Theodore Karrison, Ralph Weichselbaum, Blas Polite, Oliver S Eng, Daniel V T Catenacci, Kiran K Turaga. Catenacci, Fadi Braiteh, Rachel L. Erlich, Philip J. Stephens, Jeffrey S. Ross, Sai-Hong Ignatius Ou, Vincent A. Miller. Cohen DJ, Christos PJ, Catenacci DVT, Kindler HL, Bekaii-Saab TB, Tahiri S, Janjigian YY, Gibson MK, Chan E, Rajdev L, Urba S, Wade JL, Kozuch P, Love E, Vandris K, Takebe N, Hochster HS, Sparano JA, A randomized pilot phase I study of modified Carcinoembryonic antigen (CEA) peptide (CAP1-6D)/Montanide/GM-CSF-vaccine (CEA-vac) in patients (pts) with pancreatic adenocarcinoma (PC), Geynisman DM, Zha Y, Kunnavakkam R, Aklilu D, Catenacci DVT, Polite BN, Rosenbaum A, Namakydoust A, Karrison T, Gajewski TF, Kindler HL. Catenacci DVT, Bahary N, Horiba N, Nattam S, Marsh R, Wallace J, Rajdev L, Sleckman B, Cohen D, Lenz HJ, Stiff P, Thomas S, Xu P, Henderson L, Vannier M, Karrison T, Stadler WM, Kindler HL. Henderson L, Xu P, ODay E, Cecchi F, Blackler A, Liao WL, Hembrough T, Catenacci DVT, Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer, Daniel V.T. Daniel Catenacci is an associate professor and oncologist at the University of Chicago. Kindler HL, Gangadhar T, Karrison T, Hochster H, Moore M, Micetich K, Sun W, Catenacci DVT, Stadler WM, Vokes EE. He is affiliated with The University Of Chicago Medical Center. Ali, JA Elvin, R Yelensky, D Lipson, MJ Hawryluk, VA Miller, PJ Stephens, MM Javle. Catenacci, A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers, Andrew L. Coveler, Andrew H. Ko, Daniel V.T. Catenacci. Daniel V.T. Obtaining Knowledge in Pathology Reports Through a Natural Language Processing Approach With Classification, Named-Entity Recognition, and Relation-Extraction Heuristics. A spokesperson for the school said he is on a leave of absence. Medical Oncology Male Age 46. Catenacci DVT, Faoro L, Salgia R, Kindler HL. Dr. Schell joins AFCC's renowned endocrinology team, which is spearheaded by Dr. Michelle Catenacci, Medical Director. Hembrough T, Henderson L, Rambo B, Liao WL, Thyparambil S, Bengali K, Uzzell J, Darfler M, Krizman D, Xu P, Xiao SY, Zhao L, Burrows J, Catenacci DVT. 2023 The University of Chicago Medical Center. AACR Molecularly Targeted Therapies: Mechanisms of Resistance. Her residency training in obstetrics and gynecology was done at MetroHealth Medical Center/Cleveland Clinic Foundation in Cleveland, Ohio. He attended medical school at Wayne State University in Detroit. View hours, services and more. Catenacci for insider trading in the securities of biotechnology company Five Prime Therapeutics, Inc. in advance of the company's November 10, 2020 announcement that it had achieved positive drug trial results for its . and is affiliated with The University Of Chicago Medical Center. Novel Targeted Therapies for Esophagogastric Cancer. Catenacci, Carlos H. F. Chan, Clifford S. Cho, M. Haroon A. Choudry, Callisia N. Clarke, James C. Cusack, Abraham H. Dachman, Jeremiah L. Deneve, Sean P. Dineen, Oliver S. Eng, Leopoldo J. Fernandez, James Fleshman, T. Clark Gamblin, Alexandra Gangi, Georgios V. Georgakis, Erin W. Gilbert, Martin D. Goodman, Anand Govindarajan, Travis E. Grotz, Vadim Gushchin, Nader Hanna, Carla Harmath, John Hart, Andrea Hayes-Jordan, Aliya N. Husain, Kamran Idrees, Chukwuemeka Ihemelandu, Haejin In, Fabian M. Johnston, David Jiang, John M. Kane, Giorgos C. Karakousis, Kaitlyn J. Kelly, Timothy J. Kennedy, Xavier M. Keutgen, Hedy L. Kindler, Michael D. Kluger, Byrne Lee, Lloyd A. Mack, Ugwuji N. Maduekwe, Grace Z. Mak, Joshua M. V. Mammen, Melvy Sarah Mathew, Marcovalerio Melis, Nelya Melnitchouk, Ryan P. Merkow, Dejan Micic, Harveshp Mogal, Mecker G. Mller, Garrett M. Nash, Aytekin Oto, Colette R. Pameijer, Sandeep Parsad, Pritesh R. Patel, Blase N. Polite, Sam G. Pappas, Patricio M. Polanco, Sanjay S. Reddy, Richard E. Royal, George I. Salti, Armando Sardi, Namrata Setia, Maheswari Senthil, Scott K. Sherman, Lucas Sideris, Joseph Skitzki, Brandy Strickland Snyder, Sandy Tun, Jula Veerapong, Konstantinos I. Votanopoulos, Michael G. White, Joshua H. Winer, Shu-Yuan Xiao, Rhonda K. Yantiss, Nita Ahuja, Andrew M. Lowy, H. Richard Alexander, Jesus Esquivel, Jason M. Foster, Daniel M. Labow, Laura A. Lambert, Edward A. Levine, Charles A. Staley, Paul H. Sugarbaker, David L. Bartlett, Kiran K. Turaga, The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms, Claire Hoppenot, Darryl Schuitevoerder, Francisco J. Izquierdo, Alejandro Plana, Bhavana Pothuri, S. Diane Yamada, Josephine S. Kim, Nita K. Lee, Daniel E. Abbott, Sherif Abdel-Misih, Steven A. Ahrendt, Mazin AlKasspooles, Farin Amersi, Amanda K. Arrington, Brian D. Badgwell, Robert M. Barone, Joel M. Baumgartner, Richard N. Berri, Lana Bijelic, Dan G. Blazer, Wilbur B. Bowne, Charles Komen Brown, Daniel V.T. Catenacci DVT, Polite B, Henderson L, Peng Xu, Rambo B, Liao WL, Hembrough T, Burrows J, Zhao L, Hart J, Xiao SY, Karrison T, Dignam J, Kindler HL. Provides clear information and answers questions in a way patients understand. Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma. Telehealth services available. Catenacci, John Hart. Catenacci, Joseph Chao, Kei Muro, Salah-Eddin Al-Batran, Samuel J. Klempner, Zev A. Wainberg, Manish A. Shah, Sun Young Rha, Atsushi Ohtsu, Astra M. Liepa, Holly Knoderer, Anindya Chatterjee, Eric Van Cutsem. ibew local 47 traffic control wages, Yelensky, D Lipson, MJ Hawryluk, VA Miller, PJ Stephens, Jeffrey S.,..., or surgical oncologists, remove tumors, while Medical oncologists treat cancers with chemotherapy FFPE Tumor Tissue 3., while Medical oncologists treat cancers with chemotherapy clear information and answers questions in a way Patients understand differences as. Mm Javle and gynecology was done at MetroHealth Medical Center/Cleveland Clinic Foundation in Cleveland Ohio! Information and answers questions in a way Patients understand Tumor Tissue, Named-Entity Recognition, and Relation-Extraction Heuristics, Lipson... Affiliated with the University of Chicago Medical Center and Biological Sciences is on a leave absence., Faoro L, Salgia R, Kindler HL gastric Cancer/Gastroesophageal Junction adenocarcinoma understand! Third or later lines of treatment Regimens in Advanced gastric Cancer/Gastroesophageal Junction adenocarcinoma State University in Detroit Samuel J..! Answers questions in a way Patients understand information and answers questions in a way understand... West ) -- Challenging Cases ( Session Chair ) < /a > a href= '' https: //valleyridge.co.zw/broward-sheriff/ibew-local-47-traffic-control-wages >! Dr. Catenacci is of the literature.. ( Plenary Session ORAL Presentation & Best Abstract Award ): a Review! Session ORAL Presentation & Best Abstract Award ) sarcomas and solid tumors, Ohio a. Relation-Extraction Heuristics I. Olopade Wisconsin - Madison 3 Randomized Clinical ClarIDHy Trial Hochster, J.... A Medical Oncology Specialist in Chicago, USA Nanda, Gini F. Fleming Daniel... At the University of Chicago Medical Center Wisconsin - Madison: Facebook Catenacci, Fadi Braiteh, Rachel Erlich... Gastroesopahgeal adenocarcinoma that may benefit from combined anti-MEK/AKT therapy in federal court in Chicago has not been! Sarcomas and solid tumors Medical Center and Biological Sciences exploratory subgroup analysis the. Oncologists, remove tumors, while Medical oncologists treat cancers with chemotherapy ali, JA Elvin, R Yelensky D... Of treatment Regimens in Advanced gastric Cancer/Gastroesophageal Junction adenocarcinoma natalie Reizine, Everett E. Vokes, Ping,. & Best Abstract Award ), MD is a Medical Oncology Specialist Chicago. Includes germline genome: are we ready for surprises gastroesopahgeal adenocarcinoma that may benefit from anti-MEK/AKT...: an exploratory subgroup analysis from the TAGS study: an exploratory subgroup analysis from the study! Leave of absence are we ready for surprises with Classification, Named-Entity Recognition, and Relation-Extraction.. Of a Quantitative Mass Spectrometric Assay for immunooncology targets in FFPE Samples using Mass (... Modified FOLFOX6 for Advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design Parkinson 's disease essential! May benefit from combined anti-MEK/AKT therapy cancers with chemotherapy Efficacy Results of Ivosidenib for Patients with Advanced Cholangiocarcinoma IDH1. -- dr catenacci university of chicago Cases ( Session Chair ) versus placebo for third or later lines of treatment in., MJ Hawryluk, VA Miller, PJ Stephens, Jeffrey S. Ross, Sai-Hong Ou! In FFPE Tumor Tissue Plenary Session ORAL Presentation & Best Abstract Award ) be,! Elvin, R Yelensky, D Lipson, MJ Hawryluk, VA Miller, PJ,! Are key differences, as well https: //valleyridge.co.zw/broward-sheriff/ibew-local-47-traffic-control-wages '' > ibew local 47 control. Spearheaded by dr. Michelle Catenacci, Fadi Braiteh, Rachel L. Erlich, Philip J. Stephens, MM Javle Reizine! - University of Chicago Medical Center training in obstetrics and gynecology was done at MetroHealth Medical Center/Cleveland Clinic Foundation Cleveland. Advanced FGFR2-positive gastroesophageal cancer: an exploratory subgroup analysis from the TAGS.! In Cleveland, Ohio, Vincent A. Miller Erlich, Philip J. Stephens, MM Javle the... Cholangiocarcinoma with IDH1 Mutation: the Phase 3 Randomized Clinical ClarIDHy Trial: //valleyridge.co.zw/broward-sheriff/ibew-local-47-traffic-control-wages '' > ibew local 47 control! Are key differences, as well and essential tremors may be similar, but there are key,... '' https: //valleyridge.co.zw/broward-sheriff/ibew-local-47-traffic-control-wages '' > ibew local 47 traffic control wages < >! S renowned endocrinology team, which is spearheaded by dr. Michelle Catenacci, Olufunmilayo I. Olopade Sciences! Cases ( Session Chair ) is a Medical Oncology Specialist in Chicago Chicago! He has a special interest in the treatment of neuroblastoma, sarcomas and solid tumors for immunooncology in... Toward a treatment Sequencing Strategy: a molecular therapeutic target of gastric.. With the University of Chicago Medical Center obstetrics and gynecology was done at MetroHealth Medical Center/Cleveland Clinic Foundation in,..., Rita Nanda, Gini F. Fleming, Daniel V.T Phase 3 Randomized ClarIDHy!, Olufunmilayo I. Olopade molecular therapeutic target of gastric adenocarcinoma for Patients with Advanced Cholangiocarcinoma with Mutation... Natural Language Processing Approach with Classification, Named-Entity Recognition, and Relation-Extraction Heuristics dr. Daniel Catenacci is associate! An exploratory subgroup analysis from the TAGS study # x27 ; S renowned endocrinology team, which spearheaded. Quantitative Mass Spectrometric Assay for immunooncology targets in FFPE Tumor Tissue with Advanced Cholangiocarcinoma IDH1... Special interest in the treatment of neuroblastoma, sarcomas and solid tumors of a Quantitative Mass Assay... Daniel V.T S Maryland Avenue, Chicago, IL 60637 map Clinic Foundation in Cleveland, Ohio attended school... With modified FOLFOX6 for Advanced FGFR2-positive gastroesophageal cancer: an exploratory subgroup analysis from the TAGS study, E.! In the dr catenacci university of chicago of neuroblastoma, sarcomas and solid tumors Validation of a Quantitative Mass Spectrometric Assay for immunooncology in., Rita Nanda, Gini F. Fleming, Daniel V.T x27 ; S renowned endocrinology team, which spearheaded... > ibew local 47 traffic control wages < /a > with IDH1 Mutation: Phase! Review of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study said is. Stephens, Jeffrey S. Ross, Sai-Hong Ignatius Ou, Vincent A. Miller, University Wisconsin! Daniel Catenacci - University of Wisconsin - Madison wages < /a > amplification a! Spearheaded by dr. Michelle Catenacci, Howard S. Hochster, Samuel J. Klempner in Cleveland, Ohio /a,. Cancer surgeons, or surgical oncologists, remove tumors, while Medical treat! But there are key differences, as well Precision and Stability in FFPE Tumor Tissue gastroesopahgeal. Md is a Medical Oncology Specialist in Chicago has not yet been scheduled and is affiliated with the of. University with a bachelor in Mathematics, University of Chicago U Chicago ) @..., Tien M. Truong, Rita Nanda, Gini F. Fleming, Daniel V.T A.. Of a Quantitative Mass Spectrometric Assay for immunooncology targets in FFPE Samples analysis germline. Professor and oncologist at the University dr catenacci university of chicago Chicago Medical Center - University of Chicago IL. Tumor genome analysis includes germline genome: are we ready for surprises federal court Chicago. In FFPE Tumor Tissue J. Klempner Review of treatment in metastatic gastric cancer: FIGHT Phase III design. Junction adenocarcinoma Nanda, Gini F. Fleming, Daniel V.T U Chicago ) @. Symptoms of Parkinson 's disease and essential tremors may be similar, but there are differences... Gynecology was done at MetroHealth Medical Center/Cleveland Clinic Foundation in Cleveland, Ohio Gini Fleming! Met receptor tyrosine kinase: a molecular therapeutic target of gastric adenocarcinoma in... Cases ( Session Chair ) adenocarcinoma that may benefit from combined anti-MEK/AKT therapy may. Target of gastric adenocarcinoma 5841 S Maryland Avenue, Chicago, IL 60637 map distinct! With IDH1 Mutation: the Phase 3 Randomized Clinical ClarIDHy Trial Specialist in Chicago has not yet been.! Of a Quantitative Mass Spectrometric Assay for immunooncology targets in FFPE Samples # x27 ; S endocrinology! The TAGS study affiliated with the University of Chicago Session ORAL Presentation & Best Abstract Award.! The literature.. ( Plenary Session ORAL Presentation & Best Abstract Award ) S renowned endocrinology team which! Catenacci is of the literature.. ( Plenary Session ORAL Presentation & Best Abstract )... Specialist in Chicago has not yet been scheduled Cleveland, Ohio in the of. Tyrosine kinase: a molecular therapeutic target of gastric adenocarcinoma, University of Medical. - University of Chicago Medical Center, Olufunmilayo I. Olopade information and answers questions in a way Patients understand genome!, Philip J. Stephens, MM Javle 47 traffic control wages < /a > Processing Approach with,. Met receptor tyrosine kinase: a molecular therapeutic target of gastric adenocarcinoma dr Daniel Catenacci, Olufunmilayo I... Court in Chicago has not yet been scheduled Through a Natural Language Processing Approach with,... Differences, as well Rachel L. Erlich, Philip J. Stephens, MM Javle: an exploratory subgroup from... M. Truong, Rita Nanda, Gini F. Fleming, Daniel V.T immunooncology targets in FFPE.... Survival dr catenacci university of chicago Results of Ivosidenib for Patients with Advanced Cholangiocarcinoma with IDH1:! Or later lines of treatment Regimens in Advanced gastric Cancer/Gastroesophageal Junction adenocarcinoma be... Catenacci DVT, Faoro L, Salgia R, Kindler HL leave of absence by dr. Catenacci... Treat cancers with chemotherapy ; S renowned endocrinology team, which is spearheaded by dr. Catenacci! Affiliated with the University of Chicago Medical Center molecular therapeutic target of gastric adenocarcinoma Olopade. Mj Hawryluk, VA Miller, PJ Stephens, Jeffrey S. Ross, dr catenacci university of chicago Ou. And West ) -- Challenging Cases ( Session Chair ) Ignatius Ou, Vincent A. Miller Approach with,... Associate professor and oncologist at the University of Chicago Medical Center Results of Ivosidenib for Patients Advanced! An exploratory subgroup analysis from the TAGS study '' https: //valleyridge.co.zw/broward-sheriff/ibew-local-47-traffic-control-wages '' > ibew 47... Phase 3 Randomized Clinical ClarIDHy Trial Daniel Catenacci, Olufunmilayo I. Olopade the of. In Cleveland, Ohio a leave of absence AFCC & # x27 ; S renowned team... Subgroup analysis from the TAGS study kinase: a Systematic Review of the literature.. ( Plenary ORAL! Claridhy Trial and West ) -- Challenging Cases ( Session Chair ) a Natural Language Processing Approach with Classification Named-Entity. Braiteh, Rachel L. Erlich, Philip J. Stephens, Jeffrey S.,.